AYTU BioPharma
AYTU
39 hedge funds and large institutions have $9.81M invested in AYTU BioPharma in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
46% more capital invested
Capital invested by funds: $6.73M → $9.81M (+$3.07M)
18% more funds holding
Funds holding: 33 → 39 (+6)
2.87% less ownership
Funds ownership: 39.88% → 37.02% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$86.1K |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$74.3K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$70.6K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$65.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$175K |
| 2 |
JIP
Jaffetilchin Investment Partners
Tampa,
Florida
|
-$32.8K |
| 3 |
Renaissance Technologies
New York
|
-$12.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.85K |
| 5 |
Morgan Stanley
New York
|
-$361 |
AYTU Hedge Fund Activity: Q4 2025 in Review
39 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2025, worth a combined $9.81M — up 46% from $6.73M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AYTU positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $86.1K. The largest seller was Stonepine Capital Management, cutting an estimated $175K.
- 39 institutional investors held AYTU BioPharma (AYTU) as of Q4 2025, up from 33 in Q3 2025.
- Funds reported $9.81M of AYTU BioPharma stock for Q4 2025, up 46% quarter-over-quarter.
- 9 funds opened new AYTU BioPharma positions in Q4 2025 and 3 closed out, a net change of +6 holders.
- The largest AYTU BioPharma buyer in Q4 2025 was Two Sigma Investments, an estimated $86.1K added.
- The largest AYTU BioPharma seller in Q4 2025 was Stonepine Capital Management, an estimated $175K sold.
Based on aggregated 13F filings for Q4 2025.